Zealand Pharma A/S Stock Price Today (NSE: ZEAL)
Fundamental Score
Zealand Pharma A/S Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Zealand Pharma A/S share price today is ₹62.00, up +0.00% on NSE/BSE as of 4 August 2026. Zealand Pharma A/S (ZEAL) is a Small-cap company in the Logistics Solution Provider sector with a market capitalisation of ₹87.31 (Cr). The 52-week high for ZEAL share price is ₹125.90 and the 52-week low is ₹55.90. At a P/E ratio of 7.83x, ZEAL is currently trading below its industry average P/E of 25.01x. The company has a Return on Equity (ROE) of 12.85% and a debt-to-equity ratio of 0.22.
Zealand Pharma A/S Share Price Chart — NSE/BSE Historical Performance
Zealand Pharma A/S share price chart: -2.89% return over the past month. 52-week high ₹125.90, 52-week low ₹55.90.
Zealand Pharma A/S — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹65.00 | ₹66.00 | ₹65.00 | ₹65.60 | 3.00K (Cr) | |
| ₹67.00 | ₹67.00 | ₹67.00 | ₹67.00 | 0.00 (Cr) | |
| ₹67.00 | ₹67.00 | ₹67.00 | ₹67.00 | 0.00 (Cr) | |
| ₹67.00 | ₹67.00 | ₹67.00 | ₹67.00 | 600.00 (Cr) | |
| ₹65.00 | ₹67.95 | ₹65.00 | ₹66.60 | 2.40K (Cr) | |
| ₹68.50 | ₹68.50 | ₹68.50 | ₹68.50 | 0.00 (Cr) | |
| ₹67.00 | ₹68.50 | ₹67.00 | ₹68.50 | 2.40K (Cr) | |
| ₹63.65 | ₹65.45 | ₹63.60 | ₹64.65 | 4.80K (Cr) | |
| ₹68.00 | ₹68.00 | ₹65.00 | ₹65.00 | 4.80K (Cr) | |
| ₹65.00 | ₹68.65 | ₹65.00 | ₹68.60 | 1.80K (Cr) |
Zealand Pharma A/S — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹65.00 | ₹68.65 | ₹63.60 | ₹65.60 | +0.92% | |
| ₹71.10 | ₹71.10 | ₹65.00 | ₹68.00 | -4.36% | |
| ₹70.90 | ₹72.45 | ₹62.10 | ₹70.90 | +0.00% | |
| ₹59.95 | ₹97.00 | ₹59.95 | ₹70.90 | +18.27% | |
| ₹70.80 | ₹77.00 | ₹55.90 | ₹57.30 | -19.07% | |
| ₹71.50 | ₹90.40 | ₹71.25 | ₹79.50 | +11.19% | |
| ₹90.05 | ₹95.00 | ₹72.00 | ₹72.00 | -20.04% | |
| ₹100.05 | ₹101.80 | ₹91.50 | ₹94.00 | -6.05% | |
| ₹108.00 | ₹121.40 | ₹99.15 | ₹102.95 | -4.68% | |
| ₹116.45 | ₹120.90 | ₹101.00 | ₹106.95 | -8.16% | |
| ₹117.20 | ₹124.75 | ₹103.00 | ₹112.00 | -4.44% | |
| ₹120.10 | ₹125.90 | ₹116.00 | ₹118.00 | -1.75% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Obesity drug pipeline is a binary bet; success brings riches, failure brings ruin.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Zealand Pharma increased its share capital by DKK 10,530 on March 19, 2026, due to employee warrants being exercised at DKK 90.70 per share, raising total proceeds of DKK 955,071. The Annual General Meeting on March 26, 2026, approved all proposals except the non-binding advisory vote on the remuneration report. Zealand Pharma also established a U.S. Research Hub in Cambridge, Massachusetts, to expand drug discovery capabilities.
CORE STORY (THE REAL GAME)
Zealand Pharma is an obesity and metabolic health play, driven by its peptide R&D expertise and AI/ML platform, aiming to become a leader in the next wave of metabolic health innovation.
- Upcoming Phase 3 Survodutide data in H1 2026
- Potential USD 700M milestone payment from Roche in 2026
- Establishment of US research hub signals commitment to innovation
- Positive Phase 3 Survodutide results
- Successful Phase 2 Petrelintide data
- New partnership or acquisition in metabolic health
- Micro-cap liquidity risk
- Clinical trial failure risk
- Reliance on Roche collaboration
DII increased stake by 1.8% (small base)
Increasing demand for obesity treatments provides a strong tailwind.
Negative Free Cash Flow of ₹-5.07 Cr over the last 5 years.
3-6 month thesis hinges on clinical trial data releases. Positive results will drive a re-rating; negative results will lead to a significant sell-off.
Primary Thesis Risk
Clinical trial failure will obliterate the obesity pipeline thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Zealand Pharma A/S Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zealand Pharma A/S Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZEAL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (16.57%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 7.83 vs Industry: 25.01)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (21.15%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (36.35% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (43.69% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (8.23x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.40%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Revenue Contraction (-42.16%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-22.69% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-14.20 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.44%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Zealand Pharma A/S vs Logistics Solution Provider Peers
Peer Comparison - Logistics Solution Provider
Compare Zealand Pharma A/S with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
55.8/100 | ₹62.00₹62 | ₹87.31₹87.31 | 7.83Average 7.8 Average | 12.85%Average 12.85% Average | 16.57%Good 16.57% Good | 0.22Excellent 0.2 Excellent | 43.69%Excellent 43.69% Excellent | 36.35%Excellent 36.35% Excellent | 0.00% | |
Container Corporation of India LtdContainer Corpo... CONCOR • 531344 | 45.5/100 | ₹525.50₹526 | ₹37547.76₹37547.76 | 30.24Average 30.2 Average | 9.81%Poor 9.81% Poor | 12.41%Average 12.41% Average | 0.07Excellent 0.1 Excellent | 17.49%Excellent 17.49% Excellent | 7.15%Good 7.15% Good | 1.87% |
Delhivery LtdDelhivery Ltd... DELHIVERY • 543529 | 32.6/100 | ₹481.95₹482 | ₹37351.67₹37351.67 | 209.25Average 209.3 Average | 1.87%Poor 1.87% Poor | 2.82%Poor 2.82% Poor | 0.15Excellent 0.1 Excellent | 19.76%Excellent 19.76% Excellent | 23.57%Excellent 23.57% Excellent | 0.00% |
Blue Dart Express LtdBlue Dart Expre... BLUEDART • 526612 | 48.8/100 | ₹5160.30₹5160 | ₹11691.14₹11691.14 | 41.68Average 41.7 Average | 16.82%Good 16.82% Good | 16.64%Good 16.64% Good | 0.64Good 0.6 Good | 19.34%Excellent 19.34% Excellent | 13.31%Good 13.31% Good | 0.51% |
63.1/100 | ₹930.50₹931 | ₹7157.27₹7157.27 | 15.78Average 15.8 Average | 19.22%Good 19.22% Good | 19.45%Good 19.45% Good | 0.12Excellent 0.1 Excellent | 23.66%Excellent 23.66% Excellent | 11.90%Good 11.90% Good | 1.08% | |
TVS Supply Chain Solutions LimitedTVS Supply Chai... TVSSCS • 543965 | 33.8/100 | ₹135.11₹135 | ₹6109.06₹6109.06 | 32.83Average 32.8 Average | 9.70%Poor 9.70% Poor | 10.06%Average 10.06% Average | 1.35Average 1.4 Average | 28.84%Excellent 28.84% Excellent | 9.68%Good 9.68% Good | 0.00% |
Afcom Holdings LtdAfcom Holdings ... AFCOM • 544224 | 58.5/100 | ₹1415.30₹1415 | ₹4054.97₹4054.97 | 33.26Average 33.3 Average | 36.01%Excellent 36.01% Excellent | 33.49%Excellent 33.49% Excellent | 0.88Good 0.9 Good | 98.76%Excellent 98.76% Excellent | 111.16%Excellent 111.16% Excellent | 0.00% |
VRL Logistics LtdVRL Logistics L... VRLLOG • 539118 | 51.9/100 | ₹241.40₹241 | ₹4024.43₹4024.43 | 16.65Average 16.6 Average | 21.71%Excellent 21.71% Excellent | 18.27%Good 18.27% Good | 1.01Average 1.0 Average | 40.23%Excellent 40.23% Excellent | 12.81%Good 12.81% Good | 3.26% |
Sindhu Trade Links LimitedSindhu Trade Li... SINDHUTRAD • 532029 | 45.8/100 | ₹24.41₹24 | ₹3876.37₹3876.37 | 67.49Average 67.5 Average | 3.42%Poor 3.42% Poor | 4.44%Poor 4.44% Poor | 0.26Excellent 0.3 Excellent | 27.21%Excellent 27.21% Excellent | -10.08%Poor -10.08% Poor | 0.00% |
Mahindra Logistics LtdMahindra Logist... MAHLOG • 540768 | 35.6/100 | ₹409.50₹410 | ₹3857.23₹3857.23 | 1488.62Average 1488.6 Average | 0.32%Poor 0.32% Poor | 7.36%Poor 7.36% Poor | 0.55Good 0.6 Good | -39.59%Poor -39.59% Poor | 16.48%Excellent 16.48% Excellent | 0.64% |
Gateway Distriparks LimitedGateway Distrip... GATEWAY • 543489 | 48/100 | ₹57.97₹58 | ₹2954.92₹2954.92 | 11.46Average 11.5 Average | 11.47%Average 11.47% Average | 10.83%Average 10.83% Average | 0.28Excellent 0.3 Excellent | 22.30%Excellent 22.30% Excellent | 13.40%Good 13.40% Good | 3.38% |
Top Logistics Solution Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Container Corporation of India Ltd share price37547.76 Cr
- Delhivery Ltd share price37351.67 Cr
- Blue Dart Express Ltd share price11691.14 Cr
- Transport Corporation of India Ltd share price7157.27 Cr
- TVS Supply Chain Solutions Limited share price6109.06 Cr
Zealand Pharma A/S PE Ratio History
Historical price-to-earnings ratio for ZEAL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹7.40 | ₹215.00 | 29x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Zealand Pharma A/S Dividend History
Annual cash dividends paid by ZEAL — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹1.33 Cr |
| FY 2021 | ₹0.02 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Zealand Pharma A/S Quarterly Performance
Latest quarterly metrics for ZEAL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-42.16%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
21.15%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
36.35%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
43.69%
Compounded annual net profit growth over 5 years
Zealand Pharma A/S Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ZEAL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Zealand Pharma A/S Financial Statements
Annual income statement, balance sheet and cash flow for Zealand Pharma A/S (ZEAL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Zealand Pharma A/S
About ZEAL (Zealand Pharma A/S)
Zealand Pharma A/S (ZEAL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Logistics Solution Provider sector wi...th a current market capitalisation of ₹87.31 (Cr). Zealand Pharma A/S has delivered a Return on Equity (ROE) of 12.85% and a ROCE of 16.57%. The debt-to-equity ratio stands at 0.22, reflecting the company's capital structure. Investors tracking ZEAL share price can monitor key metrics including P/E ratio, promoter holding of 73.40%, and quarterly earnings growth.
Company Details
ZEAL Share Price: Frequently Asked Questions
What is the current share price of Zealand Pharma A/S?
Zealand Pharma A/S (ZEAL) trades at ₹62.00 on NSE. Market cap ₹87.31 (Cr). Educational data only.
What is the P/E ratio of Zealand Pharma A/S?
Zealand Pharma A/S has a P/E of 7.83x vs industry average 25.01x.
What is the Bull Run score for Zealand Pharma A/S?
Zealand Pharma A/S has a Bull Run score of 55.8/100 based on 25+ financial parameters.
Does Zealand Pharma A/S pay dividends?
Zealand Pharma A/S has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Zealand Pharma A/S?
Zealand Pharma A/S has ROE of 12.85%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Zealand Pharma A/S?
Zealand Pharma A/S has debt-to-equity of 0.22.
Is Zealand Pharma A/S a good investment?
Bull Run gives Zealand Pharma A/S a score of 55.8/100. This is not investment advice — consult a SEBI-registered advisor.